15 recruiting, 11 completed, 8 unknown, 3 active not recruiting. 12 Phase 2, 11 Phase 1, 5 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow Advanced Prostate Cancer: new trials by email Literature Review of Advanced Prostate Cancer trials Research Report on Advanced Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer QLS2401 - Advanced Prostate Cancer | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 252 | 2026-11-06 | 2026-10-13 |
| DEC003M in Prostate Cancer DEC003M - Advanced Prostate Cancer | Phase 1 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 110 | 2026-08-19 | 2026-10-14 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer Teverelix DP 180 mg - Advanced Prostate Cancer, GnRH Antagonist | Phase 2 | Not yet recruiting | Antev Ltd. | 40 | 2026-07-01 | 2026-03-12 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer GDC-1261 - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Genentech, Inc. | 260 | 2026-04-29 | 2026-10-06 |
| Lab Research Using Mini-tumors to Study Prostate Cancer Treatments HDR brachytherapy, Diagnostic biopsy - Prostate Cancer, Prostate Cancer Metastatic Disease | Recruiting | Maastricht Radiation Oncology | 600 | 2026-03-15 | 2026-04-23 | |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer HS-20093, HRS-5041 - Advanced Prostate Cancer | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 63 | 2025-08-19 | 2025-12-05 |
| Engage Psychosocial Intervention for Cancer Symptoms ENGAGE, Supportive Care - Advanced Breast Cancer, Advanced Prostate Cancer | Not applicable | Recruiting | Duke University | 190 | 2025-06-11 | 2026-03-16 |
| HS-10502 Combination Treatment in Patients With Advanced Solid Tumors HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib - Recurrent Ovarian Cancer, HER2-negative | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 157 | 2025-05-07 | 2025-06-24 |
| Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer Ga 68 PSMA-11 PET, 18F-DCFPyL PET, FDG PET - Advanced Prostate Cancer | Not applicable | Recruiting | University Health Network, Toronto | 30 | 2025-04-03 | 2026-02-12 |
| Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Darolutamide, Relugolix - Prostate Cancer, Advanced Prostate Cancer | Phase 2 | Active not recruiting | Atish Choudhury, MD | 33 | 2024-12-13 | 2026-03-09 |
| European Registry of Next Generation Imaging in Advanced Prostate Cancer Imaging - Prostate Cancer, Advanced Prostate Cancer | Recruiting | Fundacio Puigvert | 600 | 2024-09-17 | 2025-03-11 | |
| PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. Stereotactic Body Radiation Therapy - Advanced Prostate Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2024-06-27 | 2026-08-21 |
| Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer DKF-MA102 - Advanced Prostate Cancer | Phase 3 | Completed | Dongkook Pharmaceutical Co., Ltd. | 161 | 2024-05-30 | 2026-08-14 |
| Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT 18F-fluciclovine, PET/CT - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Recruiting | Brigham and Women's Hospital | 30 | 2024-02-01 | 2025-11-05 |
| Whole Body MRI in Oncology Whole Body-Magnetic Resonance Imaging (WB-MRI) - Lymphoma, Advanced Prostate Cancer | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1000 | 2023-10-26 | 2025-03-30 | |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer HRS-4357 injection - Advanced Prostate Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 49 | 2023-09-30 | 2023-08-23 |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) HRS-5041, Docetaxel injection, Abiraterone acetate tablets - Advanced Prostate Cancer | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-08-03 | 2026-08-31 |
Showing 20 of 43. Sign in to see all of them.
Prostatic Neoplasms (14) · Lower Urinary Tract Symptoms (2) · Neoplasm Metastasis (2) · Agnosia (1) · Bone Diseases (1) · Breast Neoplasms (1) · Lymphoma (1) · Monoclonal Gammopathy of Undetermined Significance (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1) · Prostatic Diseases (1) · Smoldering Multiple Myeloma (1) · Stomach Neoplasms (1) · Urogenital Diseases (1)
Neoplasms (16) · Genital Diseases (15) · Genital Diseases, Male (15) · Male Urogenital Diseases (15) · Genital Neoplasms, Male (14) · Neoplasms by Site (14) · Prostatic Diseases (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (3) · Neoplastic Processes (2) · Pathologic Processes (2) · Urological Manifestations (2) · Adnexal Diseases (1)
Abiraterone Acetate (4) · Docetaxel (4) · Prednisone (4) · Leuprolide (3) · Gonadotropin-Releasing Hormone (2) · Goserelin (2) · abiraterone (2) · enzalutamide (2) · 130-nm albumin-bound paclitaxel (1) · BID protein, human (1) · Bevacizumab (1) · Diagnostic Imaging (1) · Glucocorticoids (1) · Ipilimumab (1) · Irinotecan (1)
Centro Nacional de Investigaciones Oncologicas CARLOS III (4) · AstraZeneca (2) · Genentech, Inc. (2) · Ipsen (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Abbott (1) · Antev Ltd. (1) · Atish Choudhury, MD (1) · Brigham and Women's Hospital (1) · CCTU (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Dendreon (1) · Dongkook Pharmaceutical Co., Ltd. (1) · Duke University (1) · Eurofarma Laboratorios S.A. (1)
United States (13) · China (8) · Spain (6) · United Kingdom (5) · France (3) · Italy (3) · Netherlands (3) · Australia (2) · Canada (2) · Germany (2) · Poland (2) · South Korea (2) · Belgium (1) · Croatia (1) · Denmark (1)
David Olmos, MD (2) · Alfredo Berruti, PHD (1) · Alice Rossi (1) · Ana Marija Gjurovic (1) · Andreja Hasenohrl (1) · Atish Choudhury, MD, PhD (1) · Bruce Brown, MD (1) · Bruno Castagneto, MD (1) · Bumjin Lim, M.D. (1) · Cheol Kwak, M.D.,Ph.D (1) · Choung-Soo Kim, M.D.,Ph.D (1) · Comron Hassanzadeh, MD (1) · Curtiland Deville, M.D. (1) · David Olmos (1)
PMID 32111923, PMID 34350976, PMID 35145218, PMID 36358643, PMID 37838555, PMID 40834926, PMID 41338644
2023 (1), R01CA291768 (1), U01CA183031 (1)